Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2021-03-23

FDA Approved: TIVICAY PD — Supplemental Application (ViiV Healthcare Company)

View source ↗

Summary

FDA approved a supplemental application for Tivicay PD (dolutegravir) filed by ViiV Healthcare Company.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • TIVICAY PD (dolutegravir sodium)

Snippet

SUPPL AP for TIVICAY PD (DOLUTEGRAVIR SODIUM)